Trial Profile
Multicenter Phase II Trial of OSI-774 (Erlotinib, Tarceva) in Patients With Advanced Bronchioalveolar Cell Lung Cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Jan 2016
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 16 Jul 2010 Actual end date (1 Jun 2010) added as reported by ClinicalTrials.gov. (NCT00416650).
- 16 Jul 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov. (NCT00416650).
- 01 Feb 2007 New trial record.